scholarly journals Leukotriene Receptor Antagonists and the Risk of Neuropsychiatric Disease: Could There Be a Genetic Predisposition?

2021 ◽  
Vol 9 (12) ◽  
pp. 4298-4299
Author(s):  
Désirée Larenas-Linnemann
Keyword(s):  
Genetic Predisposition ◽  
Receptor Antagonists ◽  
Neuropsychiatric Disease ◽  
Leukotriene Receptor Antagonists ◽  
Leukotriene Receptor

Treatment and Prevention of Periprosthetic Capsular Contracture in Breast Surgery With Prosthesis Using Leukotriene Receptor Antagonists: A Meta-Analysis

2021 ◽  
Author(s):  
Andrei Pașca ◽  
Eduard-Alexandru Bonci ◽  
Codruța Chiuzan ◽  
Nicoleta Monica Jiboc ◽  
Vlad Alexandru Gâta ◽  
...  
Keyword(s):  
Subgroup Analysis ◽  
Breast Surgery ◽  
Meta Analysis ◽  
Statistical Significance ◽  
Capsular Contracture ◽  
Risk Difference ◽  
Receptor Antagonists ◽  
Leukotriene Receptor Antagonists ◽  
Treatment And Prevention ◽  
Leukotriene Receptor

Abstract Background Capsular Contracture (CC) is the most common long-term complication of breast surgery with prosthesis. Leukotriene Receptor Antagonists (LRAs) have been tested as a potential treatment; however, mixed results have been observed. Objectives This study presents a meta-analysis to clarify the treatment and prophylactic capabilities of LRAs in the management of CC. Methods A systematic literature search in the most popular English databases was performed to identify relevant primary publications. We included all studies that evaluated the treatment and preventive capabilities of LRAs using the Baker scale assessment. Results Six eligible studies were included based on predefined inclusion and exclusion criteria, totalling 2276 breasts, out of which 775 did not receive LRAs and 1501 did. Final pooled results showed that LRAs could help manage CC with a Risk Difference (RD) of -0.38 with the corresponding 95% Confidence Interval (CI) between -0.69 and -0.08, showing statistical significance at a Z value of 2.48, p=0.01. Subgroup analysis based on the type of drug used showed that only montelukast yielded statistical significance (RD=-0.27, 95% CI between -0.51 and -0.03, Z=2.20, p=0.03). Zafirlukast did not seem to influence CC. Further subgroup analysis based on treatment timing showed that prophylaxis was ineffective and only treatment for ongoing CC yielded statistical significance. Conclusions The current meta-analysis proved that LRAs could be used in the management of CC. Only treatment for the ongoing CC showed statistical significance. Montelukast seemed to be more efficient with a safer profile for adverse effects, while zafirlukast yielded no statistical significance.

Leukotriene-Receptor Antagonists and 5-Lipoxygenase Inhibitors in Asthma

1993 ◽  
Vol 27 (7-8) ◽  
pp. 898-903 ◽  
Author(s):  
Julie S. Larsen ◽  
Edward P. Acosta
Keyword(s):  
Clinical Trials ◽  
English Language ◽  
Data Extraction ◽  
Background Information ◽  
Receptor Antagonists ◽  
Lipoxygenase Inhibitors ◽  
Medline Search ◽  
Leukotriene Receptor Antagonists ◽  
Patient Tolerance ◽  
Leukotriene Receptor

OBJECTIVE: To familiarize readers with a potentially new class of compounds for treating asthma. Background information on leukotrienes is provided in addition to an indepth review of pertinent clinical trials. DATA SOURCES: Information was obtained from controlled clinical trials, abstracts, and review articles identified through a MEDLINE search of English-language articles. STUDY SELECTION: Emphasis was placed on early clinical trials that showed some benefit with these compounds as well as more recent studies using newer agents that produced more promising results. DATA EXTRACTION: Information regarding leukotriene biochemistry was extracted from basic science research and data from human studies were evaluated by the authors according to patient selection, study design, methodology, and therapeutic response. DATA SYNTHESIS: Leukotrienes have a pathophysiologic role in asthma. Two distinct but pharmacologically similar classes of leukotriene inhibitors are currently being clinically evaluated. These are leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Early clinical trials with these agents yielded unfavorable results primarily because of lack of drug potency and selectivity, poor patient tolerance, and possibly the route of administration. Subsequent studies with more potent and selective agents have further implicated leukotrienes as biochemical mediators in asthma and, consequently, have shown promising clinical outcomes with respect to pulmonary function testing and patient tolerance. CONCLUSIONS: Advancements in the pathogenesis of asthma are beginning to define a role for the leukotrienes. Although more studies are needed to assess the efficacy of leukotriene inhibitors, recent clinical trials using leukotriene-receptor antagonists and 5-lipoxygenase inhibitors indicate a potential for the expansion of therapeutic regimens currently used in the treatment of asthma.

Leukotriene Receptor Antagonists for the Treatment of Asthma in Elderly Patients

Drugs & Aging ◽  
2016 ◽  
Vol 33 (10) ◽  
pp. 699-710 ◽  
Author(s):  
Hoang Kim Tu Trinh ◽  
Ga-Young Ban ◽  
Ji-Ho Lee ◽  
Hae-Sim Park
Keyword(s):  
Elderly Patients ◽  
Receptor Antagonists ◽  
Leukotriene Receptor Antagonists ◽  
Leukotriene Receptor
Sign in / Sign up

Export Citation Format

Share Document